MP
Therapeutic Areas
Thylacine Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Undisclosed Commercial Antiviral(s) | Persistent endemic respiratory viruses | Pre-clinical |
| Undisclosed Biothreat Antiviral(s) | High-consequence viral pathogens with pandemic potential | Pre-clinical |